Neurology · Phase 2-3 · pulled 2026-11-06

Multiple sclerosis: trial sites and investigators

25 sites and 10 investigators from 178 completed and terminated Phase 2-3 trials of multiple sclerosis (last 12 years), plus 128 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Multiple sclerosis: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	University of South Florida Tampa, United States · 13 spellings merged	18 13 completed, 5 terminated	NCT05798520 NCT04458051 NCT05232825 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) completed 2025-11-14 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab completed 2025-03-11 NCT03996291 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis completed 2024-11-26 NCT04486716 A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis completed 2024-10-21	2026-02-10	22 NCT07299019 NCT07067463 NCT05269004 NCT06846281	92
2	University of Colorado Denver Aurora, United States · 13 spellings merged	11 6 completed, 5 terminated	NCT05798520 NCT04410978 NCT03161028 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) completed 2024-07-15 NCT03161028 Lipoic Acid for Progressive Multiple Sclerosis (MS) completed 2024-06-30 NCT03283826 Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis terminated 2024-01-17 Stop reason on the record: “Study was terminated as primary endpoint was not achieved” NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT03085810 Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) terminated 2023-04-27 Stop reason on the record: “The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.”	2026-02-10	10 NCT05269004 NCT04047628 NCT04586010 NCT04544449	86
3	Consultants In Neurology-Site Number:8400011 Northbrook, United States · 11 spellings merged	10 8 completed, 2 terminated	NCT06220669 NCT04458051 NCT03996291 6 trials with titles NCT06220669 A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis terminated 2026-07-13 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) completed 2025-11-14 NCT03996291 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis completed 2024-11-26 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT04410991 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) completed 2024-07-16 NCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) completed 2024-07-15	2026-07-13	7 NCT05269004 NCT07325292 NCT05134441 NCT06372145	95
4	Cleveland Clinic Cleveland, United States · 11 spellings merged	10 7 completed, 3 terminated	NCT05798520 NCT04458051 NCT04353492 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) completed 2025-11-14 NCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab completed 2025-03-11 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT05000216 COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders terminated 2024-03-28 Stop reason on the record: “The study was closed due to continued enrollment hurdles.” NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24	2026-02-10	10 NCT06846281 NCT04047628 NCT07225504 NCT07002034	91
5	Neurology Associates PA Maitland, United States · 10 spellings merged	10 8 completed, 2 terminated	NCT04458051 NCT05232825 NCT04353492 6 trials with titles NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) completed 2025-11-14 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab completed 2025-03-11 NCT03996291 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis completed 2024-11-26 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT04410991 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) completed 2024-07-16	2025-11-14	14 NCT07299019 NCT07067463 NCT05269004 NCT06846281	94
6	Neuro-Medic Janusz Zbrojkiewicz Katowice, Poland · 8 spellings merged	9 4 completed, 5 terminated	NCT06220669 NCT03232073 NCT04203498 6 trials with titles NCT06220669 A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis terminated 2026-07-13 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis terminated 2023-02-28 Stop reason on the record: “This study was terminated based on a business decision by the Sponsor.” NCT04984278 Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis terminated 2022-11-11 Stop reason on the record: “The study was terminated based on a business decision by the Sponsor.” NCT04115488 Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® completed 2022-02-07 NCT02907177 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) terminated 2020-03-26 Stop reason on the record: “sponsor decision due to low recruitment”	2026-07-13	6 NCT07299019 NCT07067463 NCT05269004 NCT05201638	73
7	Nemocnice Jihlava Jihlava, Czechia · 5 spellings merged	8 5 completed, 3 terminated	NCT05798520 NCT03599245 NCT05232825 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis terminated 2023-02-28 Stop reason on the record: “This study was terminated based on a business decision by the Sponsor.” NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes”	2026-02-10	4 NCT05269004 NCT05119569 NCT03523858 NCT06564311	87
8	University of New Mexico Albuquerque, United States · 12 spellings merged	8 7 completed, 1 terminated	NCT05798520 NCT04458051 NCT04353492 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) completed 2025-11-14 NCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab completed 2025-03-11 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT04410991 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) completed 2024-07-16 NCT03752307 Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses completed 2023-07-06	2026-02-10	10 NCT07299019 NCT05269004 NCT06846281 NCT07225504	97
9	Johns Hopkins University Baltimore, United States · 8 spellings merged	8 6 completed, 2 terminated	NCT05232825 NCT04353492 NCT03423121 6 trials with titles NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab completed 2025-03-11 NCT03423121 A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis completed 2022-07-05 NCT04767698 Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis terminated 2022-05-10 Stop reason on the record: “The funding source decided to stop funding the study.” NCT02988401 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis completed 2021-12-17 NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes”	2025-06-06	8 NCT07497399 NCT07074886 NCT04544449 NCT05123703	94
10	Royal Hallamshire Hospital Sheffield, United Kingdom · 5 spellings merged	8 5 completed, 3 terminated	NCT03387670 NCT03689972 NCT04984278 6 trials with titles NCT03387670 Multiple Sclerosis-Simvastatin Trial 2 completed 2024-08-25 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT04984278 Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis terminated 2022-11-11 Stop reason on the record: “The study was terminated based on a business decision by the Sponsor.” NCT02907177 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) terminated 2020-03-26 Stop reason on the record: “sponsor decision due to low recruitment” NCT02660359 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 terminated 2019-07-04 Stop reason on the record: “Slow recruitment of patients” NCT01910259 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial completed 2018-07-04	2024-08-25	3 NCT05201638 NCT04695080 NCT04035005	84
11	Nemocnice Teplice Teplice, Czechia · 6 spellings merged	7 4 completed, 3 terminated	NCT05798520 NCT05232825 NCT03232073 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis terminated 2023-02-28 Stop reason on the record: “This study was terminated based on a business decision by the Sponsor.” NCT04984278 Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis terminated 2022-11-11 Stop reason on the record: “The study was terminated based on a business decision by the Sponsor.” NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes”	2026-02-10	4 NCT07067463 NCT05269004 NCT06782490 NCT06700343	87
12	Neurology Clinic PC Cordova, United States · 7 spellings merged	7 5 completed, 2 terminated	NCT05798520 NCT05232825 NCT04411641 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis terminated 2023-02-28 Stop reason on the record: “This study was terminated based on a business decision by the Sponsor.” NCT04984278 Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis terminated 2022-11-11 Stop reason on the record: “The study was terminated based on a business decision by the Sponsor.” NCT02545868 A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis completed 2021-09-21	2026-02-10	9 NCT07299019 NCT07067463 NCT05269004 NCT07225504	86
13	Washington University School of Medicine St Louis, United States · 9 spellings merged	7 4 completed, 3 terminated	NCT05798520 NCT06083753 NCT05000216 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT06083753 Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis completed 2025-08-04 NCT05000216 COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders terminated 2024-03-28 Stop reason on the record: “The study was closed due to continued enrollment hurdles.” NCT03283826 Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis terminated 2024-01-17 Stop reason on the record: “Study was terminated as primary endpoint was not achieved” NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes”	2026-02-10	15 NCT07299019 NCT07067463 NCT05269004 NCT06782490	87
14	CHU de Strasbourg Strasbourg, France · 13 spellings merged	7 6 completed, 1 terminated	NCT03599245 NCT03232073 NCT03689972 6 trials with titles NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT03085810 Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) terminated 2023-04-27 Stop reason on the record: “The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.” NCT03122652 Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome completed 2022-10-04 NCT02587195 A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period completed 2021-08-31	2025-07-17	12 NCT05269004 NCT06675955 NCT07282574 NCT03958877	92
15	Raleigh Neurology Associates Raleigh, United States · 5 spellings merged	7 4 completed, 3 terminated	NCT04140305 NCT03232073 NCT03689972 6 trials with titles NCT04140305 Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) terminated 2025-05-15 Stop reason on the record: “Business objective has changed” NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis terminated 2023-02-28 Stop reason on the record: “This study was terminated based on a business decision by the Sponsor.” NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes” NCT02637856 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) completed 2019-05-03	2025-05-15	5 NCT05269004 NCT07325292 NCT04544449 NCT06141473	87
16	Hospital Universitario Virgen Macarena Seville, Spain · 5 spellings merged	6 4 completed, 2 terminated	NCT03540485 NCT03599245 NCT05232825 6 trials with titles NCT03540485 Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis terminated 2026-02-18 Stop reason on the record: “Early termination due to operational feasibility reasons, resulting from a slow recruitment rate and logistical and financial difficulties that prevent reaching the planned sample size within the stud” NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT02907177 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) terminated 2020-03-26 Stop reason on the record: “sponsor decision due to low recruitment”	2026-02-18	11 NCT05269004 NCT07074886 NCT07161258 NCT07282574	86
17	COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika Gdansk, Poland · 7 spellings merged	6 5 completed, 1 terminated	NCT05798520 NCT03599245 NCT03232073 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT04115488 Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® completed 2022-02-07 NCT02907177 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) terminated 2020-03-26 Stop reason on the record: “sponsor decision due to low recruitment” NCT02294058 Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) completed 2016-12-22	2026-02-10	4 NCT07067463 NCT04544436 NCT04586023 NCT04548999	91
18	Fakultni nemocnice u sv. Anny v Brne Brno, Czechia · 7 spellings merged	6 4 completed, 2 terminated	NCT05798520 NCT03599245 NCT05232825 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT02907177 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) terminated 2020-03-26 Stop reason on the record: “sponsor decision due to low recruitment” NCT02660138 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 terminated 2019-02-14 Stop reason on the record: “Low recruitment of patients” NCT02294058 Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) completed 2016-12-22	2026-02-10	5 NCT05269004 NCT06782490 NCT05119569 NCT06700343	79
19	IRCCS Istituto Neurologico Neuromed Pozzilli, Italy · 5 spellings merged	6 4 completed, 2 terminated	NCT05798520 NCT03599245 NCT05232825 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT05232825 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis completed 2025-06-06 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT02907177 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) terminated 2020-03-26 Stop reason on the record: “sponsor decision due to low recruitment” NCT03387046 A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) terminated 2019-01-11 Stop reason on the record: “Study was terminated early due to slow recruitment rate.”	2026-02-10	8 NCT07299019 NCT07067463 NCT07074886 NCT04544436	76
20	University of Kansas Medical Center Kansas City, United States · 9 spellings merged	6 4 completed, 2 terminated	NCT05798520 NCT06083753 NCT04411641 6 trials with titles NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) completed 2026-02-10 NCT06083753 Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis completed 2025-08-04 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT03283826 Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis terminated 2024-01-17 Stop reason on the record: “Study was terminated as primary endpoint was not achieved” NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes” NCT02294058 Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) completed 2016-12-22	2026-02-10	17 NCT07497399 NCT07299019 NCT07067463 NCT05269004	91
21	Providence Multiple Sclerosis Center Portland, United States · 4 spellings merged	6 5 completed, 1 terminated	NCT04458051 NCT04411641 NCT04410978 6 trials with titles NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) completed 2025-11-14 NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) completed 2024-08-29 NCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) completed 2024-07-15 NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes” NCT02637856 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) completed 2019-05-03 NCT02294058 Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) completed 2016-12-22	2025-11-14	1 NCT06372145	96
22	University of Texas Southwestern Medical Center Dallas, United States · 4 spellings merged	6 3 completed, 3 terminated	NCT03993171 NCT04410978 NCT04815967 6 trials with titles NCT03993171 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. completed 2025-07-31 NCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) completed 2024-07-15 NCT04815967 Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity terminated 2023-04-23 Stop reason on the record: “Company/sponsor business decision; not due to or related to any safety concerns” NCT02688985 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) completed 2023-04-11 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis terminated 2023-02-28 Stop reason on the record: “This study was terminated based on a business decision by the Sponsor.” NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes”	2025-07-31	3 NCT04047628 NCT04548999 NCT06735248	88
23	National Hospital for Neurology and Neurosurgery, London, United Kingdom · 6 spellings merged	6 5 completed, 1 terminated	NCT03599245 NCT03387670 NCT03689972 6 trials with titles NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT03387670 Multiple Sclerosis-Simvastatin Trial 2 completed 2024-08-25 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT02660359 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 terminated 2019-07-04 Stop reason on the record: “Slow recruitment of patients” NCT01910259 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial completed 2018-07-04 NCT02542787 Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis completed 2017-10-01	2025-07-17	1 NCT04548999	94
24	Recherche Sepmus Inc. Greenfield Park, Canada · 3 spellings merged	6 4 completed, 2 terminated	NCT03599245 NCT03283826 NCT03232073 6 trials with titles NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT03283826 Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis terminated 2024-01-17 Stop reason on the record: “Study was terminated as primary endpoint was not achieved” NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT03689972 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration completed 2023-07-24 NCT03085810 Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) terminated 2023-04-27 Stop reason on the record: “The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.” NCT02637856 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) completed 2019-05-03	2025-07-17	5 NCT05269004 NCT04544436 NCT04544449 NCT03523858	90
25	The Ottawa Hospital - General Campus Ottawa, Canada · 6 spellings merged	6 4 completed, 2 terminated	NCT03599245 NCT03161028 NCT03232073 6 trials with titles NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) completed 2025-07-17 NCT03161028 Lipoic Acid for Progressive Multiple Sclerosis (MS) completed 2024-06-30 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis completed 2024-01-16 NCT03085810 Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) terminated 2023-04-27 Stop reason on the record: “The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.” NCT02936037 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) terminated 2020-04-23 Stop reason on the record: “Sponsor decision for business purposes” NCT02239393 Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study completed 2019-12-01	2025-07-17	5 NCT05269004 NCT06782490 NCT06700343 NCT04544449	92

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Multiple sclerosis: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Vijayshree Yadav VA Portland Health Care System, Portland, OR	2	NCT04267926 NCT03166800	PMID 42966337 Multiple sclerosis and related disorders, 2026 · High match PMID 40976206 Multiple sclerosis and related disorders, 2025 · High match
2	Jeremy Chataway University College, London	2	NCT03387670 NCT01910259	PMID 42784778 Neurology, 2026 · High match PMID 42487354 Multiple sclerosis (Houndmills, Basingstoke, England), 2026 · Medium match PMID 42440661 Brain communications, 2026 · High match
3	Luanne Metz University of Calgary	2	NCT04291456 NCT02087631	PMID 35848622 Multiple sclerosis (Houndmills, Basingstoke, England), 2022 · High match PMID 35669877 Frontiers in neurology, 2022 · High match PMID 34082329 Multiple sclerosis and related disorders, 2021 · High match
4	Tarun Singhal Brigham and Women's Hospital	2	NCT04510220 NCT04144257	PMID 42949125 Brain and behavior, 2026 · High match PMID 40580802 Journal of the neurological sciences, 2025 · High match PMID 40103263 Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2025 · High match
5	Pavan Bhargava Johns Hopkins University	2	NCT04767698 NCT03423121	PMID 42912879 Neurology(R) neuroimmunology & neuroinflammation, 2026 · High match PMID 42908053 Annals of clinical and translational neurology, 2026 · High match
6	Roman Ivanov JSC BIOCAD	2	NCT04056897 NCT02744222	No paper matched at High or Medium confidence
7	Marcus Koch University of Calgary	2	NCT02913157 NCT02308137	PMID 41858174 Multiple sclerosis (Houndmills, Basingstoke, England), 2026 · High match PMID 41605625 Journal of neurology, neurosurgery, and psychiatry, 2026 · High match PMID 41072954 Journal of neurology, neurosurgery, and psychiatry, 2026 · High match
8	Dr. Bill Brashier Genesis Institute of Cellular Medicine	2	NCT02418325 NCT02638038	No paper matched at High or Medium confidence
9	Yendry Ventura Carmenate Abu Dhabi Stem Cells Center	1	NCT05168384	No paper matched at High or Medium confidence
10	Renger Witkamp Wageningen University	1	NCT07840924	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.